矿物化治疗报告了新高血压药物洛伦德罗斯塔特的成功第三期试验结果. Mineralys Therapeutics reports successful Phase 3 trial results for new hypertension drug lorundrostat.

矿物治疗公司宣布了针对治疗失控或抗性高血压的药物洛伦德罗斯塔特的第三期试验的成功结果. Mineralys Therapeutics announced successful results from its Phase 3 trial for lorundrostat, a drug aimed at treating uncontrolled or resistant hypertension. 该研究涉及1 000多名病人,表明静脉血压显著下降,第6周减少16.9毫米Hg,第12周减少19毫米Hg。 The study, involving over 1,000 patients, showed a significant reduction in systolic blood pressure, with a decrease of 16.9 mmHg at Week 6 and 19 mmHg at Week 12. 该药物在超高血压问题欧洲会议上作了介绍,并表现出良好的安全和可容忍性。 The drug was presented at the European Meeting on Hypertension and demonstrated good safety and tolerability.